Equities research analysts expect that Fate Therapeutics Inc (NASDAQ:FATE) will announce sales of $1.85 million for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Fate Therapeutics’ earnings, with estimates ranging from $1.03 million to $2.13 million. Fate Therapeutics reported sales of $1.03 million during the same quarter last year, which indicates a positive year-over-year growth rate of 79.6%. The firm is expected to issue its next quarterly earnings results on Wednesday, November 7th.

On average, analysts expect that Fate Therapeutics will report full year sales of $4.74 million for the current fiscal year, with estimates ranging from $4.00 million to $5.21 million. For the next fiscal year, analysts expect that the business will post sales of $2.54 million per share, with estimates ranging from $1.03 million to $4.11 million. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for Fate Therapeutics.

Fate Therapeutics (NASDAQ:FATE) last issued its earnings results on Monday, August 6th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.05). The business had revenue of $1.00 million during the quarter, compared to analyst estimates of $1.02 million. Fate Therapeutics had a negative net margin of 1,387.53% and a negative return on equity of 95.07%. The company’s revenue for the quarter was up .0% on a year-over-year basis.

A number of equities analysts recently commented on the company. BidaskClub downgraded Fate Therapeutics from a “buy” rating to a “hold” rating in a report on Friday. HC Wainwright restated a “hold” rating and issued a $12.00 price objective on shares of Fate Therapeutics in a report on Tuesday, August 7th. Zacks Investment Research upgraded Fate Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, August 6th. Citigroup assumed coverage on Fate Therapeutics in a report on Wednesday, August 1st. They issued a “buy” rating and a $20.00 price objective on the stock. Finally, Wedbush restated an “outperform” rating and issued a $19.00 price objective on shares of Fate Therapeutics in a report on Tuesday, August 7th. Four equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Fate Therapeutics presently has a consensus rating of “Buy” and an average price target of $16.86.

NASDAQ:FATE traded down $0.13 during mid-day trading on Friday, reaching $11.63. The stock had a trading volume of 357,400 shares, compared to its average volume of 611,827. Fate Therapeutics has a fifty-two week low of $3.50 and a fifty-two week high of $14.45. The company has a market capitalization of $632.48 million, a P/E ratio of -11.40 and a beta of 1.76. The company has a debt-to-equity ratio of 0.25, a quick ratio of 4.92 and a current ratio of 4.92.

Large investors have recently added to or reduced their stakes in the stock. First Mercantile Trust Co. increased its holdings in Fate Therapeutics by 113.7% in the second quarter. First Mercantile Trust Co. now owns 12,899 shares of the biopharmaceutical company’s stock worth $146,000 after buying an additional 6,863 shares during the last quarter. Alps Advisors Inc. bought a new stake in Fate Therapeutics during the second quarter worth approximately $870,000. Trexquant Investment LP bought a new stake in Fate Therapeutics during the first quarter worth approximately $179,000. Schwab Charles Investment Management Inc. boosted its position in Fate Therapeutics by 47.7% during the first quarter. Schwab Charles Investment Management Inc. now owns 97,500 shares of the biopharmaceutical company’s stock worth $952,000 after purchasing an additional 31,500 shares during the period. Finally, Boston Advisors LLC boosted its position in Fate Therapeutics by 12.8% during the second quarter. Boston Advisors LLC now owns 58,030 shares of the biopharmaceutical company’s stock worth $658,000 after purchasing an additional 6,570 shares during the period. Hedge funds and other institutional investors own 80.62% of the company’s stock.

About Fate Therapeutics

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; FT500 induced pluripotent stem cells (iPSC)-derived NK cell product candidate for the treatment of advanced solid tumors; FT516 engineered iPSC-derived NK cell product candidate for the treatment of hematologic/solid tumors; and FT819 engineered chimeric antigen receptor 19 iPSC-derived T-cell product candidate for hematologic/solid tumors.

Read More: What is a Fiduciary?

Get a free copy of the Zacks research report on Fate Therapeutics (FATE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.